Our platform is capable of assessing cellular avidity, the total binding strength between immune and target cells, to precisely identify and select the most potent immunotherapy candidates.
By uniting robust characterisation with high-throughput sorting and isolation of viable cells, the platform accelerates lead discovery and streamlines R&D workflows. Scientists can make earlier, more confident decisions—reducing risk, saving time, and driving the development of next-generation cell therapies forward.
Physiologically relevant
Captures the full complexity of immune–target cell interactions to deliver robust, in vivo–relevant insights into therapeutic efficacy.
High throughput
Capable of analysing cellular avidity across tens of thousands of single immune–target cell interactions per run, and scalable to millions.
Simple and Rapid
Condenses immune cell characterisation, sorting, isolation, and selection into a single rapid step by leveraging cellular avidity.
Label-free
Utilises fluid shear and cellular avidity to sort and isolate immune cells without labels, preserving native states and simplifying preparation.
Gentle & Integrable
Maintains the functionality of selected cells for immediate downstream analysis, testing, and manufacturing—seamlessly integrating into existing workflows.
Adaptable
Adapts to all solid tumours and adherent target cells across receptor-directed and receptor-agnostic cellular immunotherapy modalities.
Artificial bead
Peptide MHC
CD8 co-receptor
T cell receptor
TCR T cell
In cellular immunotherapies, affinity is commonly measured because it offers a quick snapshot of the strength of a single binding interaction between a receptor, like a T-cell receptor, and its target antigen. It is useful for understanding the initial connection, but it does not capture the full picture of immune cell behavior in the complex, dynamic environment of the body.
While high affinity suggests the strength of the initial bond, it doesn’t account for the many other types of interactions between living cells, how strongly immune cells are activated, or how they maintain their engagement over time.
To truly understand and predict immune cell effectiveness in eradicating cancer in animals and patients, we must go beyond affinity and capture avidity.
Target cell
TCR T cell
Immunological synapse
Co-stimulatory molecules
T cell receptor
Peptide MHC
CD8 co-receptor
Adhesion molecules
As cellular immunotherapies grow in complexity, there’s an increasing need for tools that provide meaningful, predictive insights. That’s where cellular avidity comes in.
Avidity, the total binding strength between immune and target cells, serves as a powerful biomarker for immune cell functionality. Unlike traditional markers, we capture the full spectrum of dynamic, live cell interactions that drive immune cell activation and therapeutic efficacy.
Avidity is influenced by key factors, including receptor density, individual affinities, and the engagement of co-receptors within the immunological synapse. This comprehensive approach allows us to measure what truly matters: the functional potential of each immune cell, offering a deeper, more accurate prediction of therapeutic success.